Notice of Results

RNS Number : 1190X
Allergy Therapeutics PLC
08 August 2018
 



 

Allergy Therapeutics plc

("Allergy Therapeutics" or the "Group")

 

Notice of Preliminary Results

 

8 August 2018 Allergy Therapeutics (AIM:AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, will issue its preliminary results for the year ended 30 June 2018 on Wednesday 26 September 2018.

 

Manuel Llobet, Chief Executive Officer, and Nick Wykeman, Chief Financial Officer, will hold a presentation and conference call for analysts on the day of results at 10:30am BST at the offices of Panmure Gordon & Co, One New Change, London, EC4M 9AF.

 

Please contact Consilium Strategic Communications for further details.

 

- ENDS -

 

For further information, please contact:

 

Allergy Therapeutics

+44 (0) 1903 845 820

Manuel Llobet, Chief Executive Officer

Nick Wykeman, Finance Director

 

Panmure Gordon

+44 (0) 20 7886 2500

Freddy Crossley / Emma Earl, Corporate Finance

 

Consilium Strategic Communications

+44 20 3709 5700

Mary-Jane Elliott / David Daley / Nicholas Brown / Olivia Manser

allergytherapeutics@consilium-comms.com

 

Stern Investor Relations, Inc.

+1 212 362 1200

Christina Tartaglia

christina@sternir.com

 

 

Notes for editors:

 

About Allergy Therapeutics

Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional fourteen countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development. Adjuvant systems to boost performance of vaccines outside allergy are also in development.

Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics is headquartered in Worthing, UK with more than 11,000m2 of state-of-the-art MHRA-approved manufacturing facilities and laboratories. The Group, which has achieved double digit compound annual growth since formation, employs c.500 employees and is listed on the London Stock Exchange (AIM:AGY). For more information, please see www.allergytherapeutics.com.

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NORKMGGRVNKGRZM
UK 100

Latest directors dealings